Results Healthcare are delighted to have been the exclusive financial advisor to Sovereign Capital Partners on the divestment of Xendo B.V. to ProPharma Group (a Linden Capital Partners LLC investment).
Xendo, headquartered in The Netherlands with offices in Germany and Sweden, is a leading provider of regulatory affairs, compliance, validation and pharmacovigilance consulting and outsourced services. The company helps biotech, pharmaceutical and medical device companies through all stages of the life cycle of their products. The firm has over 25 years’ experience of helping companies navigate the complex regulatory compliance landscape. Xendo brings with them 200+ experienced professionals offering their expertise on strategic advice and project management.
Sovereign completed a management buy-out of Xendo in 2016 and went on to successfully develop the business through a strategy of organic and acquisitive growth.
ProPharma Group is an industry leader providing pharmacovigilance, medical information, validation, compliance and technical services to the pharmaceutical, biotechnology, medical device and related industries. The firm is headquartered in Overland Park, Kansas and have offices across the US and around the world.
The deal brings together two leading players in the pharmaceutical specialist consulting sector, adding significant depth and breadth to the service offering of ProPharma and increasing their global footprint in key international markets.
Jose Rodriguez, Director, Sovereign Capital Partners commented:
“Results Healthcare have given us hands-on support and clear guidance every step of the way. They have worked diligently throughout the process and have been committed to achieving a successful outcome.”